Protean & ChromaCode Bring Rapid Cancer Diagnostics to Patients
Protean is excited to partner with ChromaCode to bring rapid and innovative lung cancer diagnostic technologies to oncologists and patients.
This will help guide treatment decisions, and accelerate access to treatments for lung cancer patients. Contact us for information on our early access program at info@proteanbiodx.com
CARLSBAD, Calif. /PRNewswire/
Published August 10, 2023
An excerpt from the original article is posted below:
ChromaCode, Inc., a genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients, and physicians, today announced a strategic partnership with Protean BioDiagnostics Inc., a CAP/CLIA-accredited, high-complexity laboratory specializing in developing and commercializing advanced cancer diagnostic technologies. This partnership's goal is to introduce a non-small cell lung cancer (NSCLC) assay, based on ChromaCode's state-of-the-art High Definition PCR (HDPCR™) multiplexing technology, via an early access program.
…
The assay holds the potential to address the challenges faced by NSCLC patients, who often encounter barriers to accessing advanced diagnostic technologies due to cost, slow turnaround times and inadequate tissue samples.
“This strategic partnership with Protean marks a significant step towards bringing the HDPCR NSCLC assay to Florida, a state accounting for approximately 10% of cancer incidence in the US.”
"This strategic partnership with Protean marks a significant step towards bringing the HDPCR NSCLC assay to Florida, a state accounting for approximately 10% of cancer incidence in the US," said Padma Sundar, Chief Business Officer of ChromaCode. "This partnership aligns with our mission to increase availability of advanced diagnostic technologies, ensuring that medical laboratories have access to cutting-edge tools that can transform the landscape of cancer care."
Anthony M. Magliocco, MD, FRCPC, FCAP, Protean's President and CEO, added, "We value the rapid turnaround and clinically relevant markers of the HDPCR™ NSCLC assay. We see a real opportunity to collaborate with commercial payors, U.S. Department of Veterans Affairs, and other government agencies, to establish coverage and reimbursement for this revolutionary technology. There is a substantial potential for HDPCR™ in the field of oncology." Protean plans to add this innovative diagnostic technology to its cutting-edge, clinical precision oncology platform Protean MAPS™.
The ultimate goal of the strategic partnership between ChromaCode and Protean is to extend the benefits of affordable and easily accessible assays that ensure rapid and precise diagnoses to a diverse range of patients in both Florida and the rest of the USA.
For further information, please contact:
Anthony Magliocco MD
CEO & President of Protean BioDiagnostics
Email: info@proteanbiodx.com
Phone: 1 (813) 817 2042
About Protean BioDiagnostics
Protean is an innovative diagnostic company developing new approaches to improving precision medicine including inventing digital pathology tools to improve cancer screening and detection.
Protean MAPS™ is the only unique precision medicine system that provides easy access to advanced comprehensive laboratory diagnostic tests and easy to understand reports along with telemedicine support. Protean’s mission is to accelerate and bring optimized precision care to all cancer patients regardless of where they live.